Medicine - Programa de Formación Médica Continuada Acreditado, Год журнала: 2023, Номер 13(92), С. 5452 - 5462
Опубликована: Дек. 1, 2023
Stresses, Год журнала: 2025, Номер 5(1), С. 7 - 7
Опубликована: Янв. 15, 2025
Chronic pain represents a complex and debilitating condition that affects millions of people worldwide, significantly compromising their quality life. The conventional approach to treating this type often relies on the use opioid analgesics anti-inflammatory drugs. While these agents are effective in short term, they present several limitations, including risk dependence, severe side effects, and, some cases, ineffectiveness reducing pain. In context, medical cannabis has emerged as promising therapeutic alternative, given its potential ability relieve effectively with favorable safety profile. This work aims provide comprehensive up-to-date review existing literature effects treatment chronic Cannabis sativa contains pharmacologically active compounds, most prominent which delta-9-tetrahydrocannabinol (∆9-THC) cannabidiol (CBD), interact body’s endocannabinoid system, thereby modulating response. Clinical evidence shown cannabinoids can reduce intensity pain, particularly cases neuropathy, multiple sclerosis, arthritis, other painful conditions unresponsive treatments. However, full integration into clinical practice faces significant obstacles, need for standardized dosing, long-term data, regulatory frameworks. These issues, alongside concerns over adverse drug interactions, must be addressed unlock cannabinoids, patients, who endure both physical suffering added burden stress.
Язык: Английский
Процитировано
1
International Journal of Mental Health and Addiction, Год журнала: 2025, Номер unknown
Опубликована: Фев. 7, 2025
Язык: Английский
Процитировано
0
Psychological Medicine, Год журнала: 2025, Номер 55
Опубликована: Янв. 1, 2025
Abstract Cannabis use is highly prevalent in people with schizophrenia and related to adverse clinical outcomes, including relapse hospitalization. However, the relationship between cannabis suicide remains inconclusive. This study aimed systematically review meta-analyze suicide-related outcomes schizophrenia. A comprehensive search of Medline, Embase, PsycINFO for cross-sectional, case-control, longitudinal studies was conducted using terms from database inception November 2024 inclusive. Computation odds ratios (ORs) hazard (HRs) performed random effects models DerSimonian-Laird estimation. All were appraised quality. We also evaluated heterogeneity, publication bias sub-group analyses meta-regression. Twenty-nine comprising 36 samples met eligibility criteria. not associated death or suicidal ideation but risks (HR = 1.21, 95% CI 1.04 – 1.40) attempted (OR 1.40, 1.16 1.68). While between-sample heterogeneity moderate ( I 2 39.6%, p 0.03), there no bias. Summary remained significant most sub-groups, just failed reach significance 0.97 1.68) investigating first episode 1.24, 0.99 1.55). significantly some, all, More work needed examine potential mechanisms relationships.
Язык: Английский
Процитировано
0
Heliyon, Год журнала: 2024, Номер 10(6), С. e27524 - e27524
Опубликована: Март 1, 2024
Ulcerative colitis (UC) is a gastrointestinal disease with an unknown etiology that severely affects patients' quality of life. Acupuncture and moxibustion therapies are effective in the treatment UC, but existing systematic reviews (SRs) meta-analyses (MAs) on this subject have variable methodological outcome quality. Therefore, study aimed to summarize evaluate evidence SRs MAs provide more reliable for clinical practice. Data were extracted from seven databases through search evaluated terms quality, reporting risk bias, using AMSTAR-2, PRISMA, ROBIS, GRADE systems, respectively. Ten studies finally included, all them showed many problems overall design outcomes. Because lack high-quality support findings studies, we should take conclusion caution strictly implement registration, design, implementation trials based results future studies.
Язык: Английский
Процитировано
2
Psychiatry Research, Год журнала: 2024, Номер 333, С. 115757 - 115757
Опубликована: Янв. 27, 2024
Язык: Английский
Процитировано
2
Опубликована: Апрель 25, 2024
Public perception contrasts scientific findings on the depression-related effects of cannabis. However, earlier studies were performed when cannabis was predominantly illegal, its production mostly uncontrolled, and idea medical incipient only. We hypothesized that recent changes in attitudes legislations may have favorably affected research. In addition, publication bias against also decreased. To investigate this hypothesis, we conducted a systematic review research published over last three years. found 156 relevant studies. most cross-sectional studies, depression higher those who consumed than did not. An increase consumption typically followed by an depression, whereas withdrawal from ameliorated cases. Albeit reduced none these placebo controlled. clinical same period, average effect size larger investigated plausibility antidepressant reviewing molecular pharmacological Taken together, reviewed do not support herbal
Язык: Английский
Процитировано
1
Asian Journal of Psychiatry, Год журнала: 2024, Номер 101, С. 104237 - 104237
Опубликована: Сен. 6, 2024
Язык: Английский
Процитировано
1
South African Journal of Botany, Год журнала: 2024, Номер 175, С. 15 - 31
Опубликована: Окт. 11, 2024
Язык: Английский
Процитировано
1
Harm Reduction Journal, Год журнала: 2024, Номер 21(1)
Опубликована: Ноя. 6, 2024
Abstract Background Canada has one of the highest prevalence cannabis use globally, particularly among young adults aged 20–24 (50%) and youth 16–19 (37%). In 2018, legalized recreational with aim protecting by restricting their access raising public awareness health risks. However, there been limited qualitative research on perceptions harms associated since legalization, which is crucial for developing effective harm reduction strategies. This study examined from perspectives youth, parents, service providers. We explored how participants described perceived risks or use, as well they own others’ approaches to reducing cannabis-related harms. Methods used a community-based participatory approach in partnership Families Addiction Recovery (FAR), national charity founded parents addiction issues. Virtual semi-structured interviews were conducted, data analyzed using thematic analysis. Results The included 88 three key groups ( n = 31 26 providers). Two main themes emerged regarding use: (1) concerns about harms, including addiction, brain development, impact family, various adverse effects areas such motivation, concentration, finances, employment, education, physical mental health; (2) minimization featuring conflicting messages, normalization, being less harmful than other substances. Additionally, two related identified: implementation reduction, challenges implementing approach. Specific each participant group noted, along structural barriers unavailable inaccessible services, easy cannabis, inadequate insufficient information lower-risk guidelines. Conclusions Youth significant concern that requires multi-pronged Developing youth-centered strategies recognize developmental needs vulnerabilities important role families, imperative.
Язык: Английский
Процитировано
1
Expert Opinion on Pharmacotherapy, Год журнала: 2024, Номер 25(6), С. 695 - 703
Опубликована: Апрель 12, 2024
About one-fifth of cannabis users, the most commonly used illicit substance, have use disorder (CUD). Psychiatric disorders and suicide are more common in these patients, disability-adjusted life years were reported to be 0.69 million. Pharmacotherapy for CUD is an unmet public health need, as current evidence-based therapies limited efficacy.
Язык: Английский
Процитировано
0